1-keto-1,2,3,4-tetrahydrophenanthrene profile

1-keto-1,2,3,4-tetrahydrophenanthrene, also known as **1-ketotetrahydrophenanthrene**, is a cyclic ketone compound. It's a derivative of phenanthrene, a polycyclic aromatic hydrocarbon (PAH).

Here's why it's important for research:

* **Model compound for PAH studies:** 1-ketotetrahydrophenanthrene is often used as a model compound in studies of the metabolism and toxicity of PAHs. This is because it shares structural similarities with many PAHs, and its relatively simple structure makes it easier to study.
* **Precursor to other compounds:** This compound can be used as a starting material for the synthesis of other important molecules, including various pharmaceuticals and natural products.
* **Potential biological activity:** Research suggests that 1-ketotetrahydrophenanthrene might exhibit biological activity, including potential anti-inflammatory and antioxidant properties. However, more research is needed to fully understand its effects on biological systems.

**Some key aspects of its structure and properties:**

* **Structure:** It has a fused ring system with a carbonyl group (C=O) at the 1-position. This carbonyl group plays a significant role in its chemical reactivity.
* **Reactivity:** The carbonyl group makes 1-ketotetrahydrophenanthrene susceptible to reactions like nucleophilic attack and reduction.
* **Spectroscopy:** It exhibits characteristic spectral properties that can be used to identify and study its structure, including UV-Vis, IR, and NMR spectra.

**Ongoing research focuses on:**

* **Understanding its metabolism and toxicity:** Researchers are studying how this compound is processed by the body and its potential effects on health.
* **Developing new synthetic methods:** Scientists are exploring new ways to synthesize 1-ketotetrahydrophenanthrene and related compounds for use in medicinal chemistry and other applications.
* **Exploring its biological activity:** Researchers are investigating the potential therapeutic uses of this compound and its derivatives, particularly in areas like inflammation and oxidative stress.

In summary, 1-keto-1,2,3,4-tetrahydrophenanthrene is a valuable tool for research due to its structural similarity to PAHs, its use as a precursor for other compounds, and its potential biological activity. Further research is needed to fully understand its properties and applications.

1-keto-1,2,3,4-tetrahydrophenanthrene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	225683
CHEMBL ID	88130
SCHEMBL ID	7413330
MeSH ID	M0365807

Synonym
CHEMBL88130 ,
1-keto-1,2,3,4-tetra-hydrophenanthrene
nsc-15301
nsc15301
mls002638423 ,
1(2h)-phenanthrone,4-dihydro-
nsc117487
1,3,4-tetrahydrophenanthren-1-one
1,3,4-tetrahydro-1-oxophenanthrene
1(2h)-phenanthrenone,4-dihydro-
573-22-8
1-oxo-1,3,4-tetrahydrophenanthrene
nsc-117487
1,2,3,4-tetrahydrophenanthren-1-one
smr001547904
3,4-dihydro-2h-phenanthren-1-one
bdbm50146059
3,4-dihydrophenanthren-1(2h)-one
3,4,-dihydro-2h-phenanthren-1-one
oxo-1,2,3,4-tetrahydrophenanthrene
KBARGPSSEIXDQU-UHFFFAOYSA-N
3,4-dihydro-2h-phenantren-1-one
HMS3089J08
AKOS006229441
SCHEMBL7413330
1-keto-1,2,3,4-tetrahydro-phenanthren
1,2,3,4-tetrahydro-1-phenanthrenone
DTXSID50280072
1-oxo-1,2,3,4-tetrahydrophenanthrene
AM9379
ran6r458ln ,
1-keto-1,2,3,4-tetrahydrophenanthrene
3,4-dihydro-1(2h)-phenanthrenone
1(2h)-phenanthrenone, 3,4-dihydro-

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
chromobox protein homolog 1	Homo sapiens (human)	Potency	79.4328	0.0060	26.1688	89.1251	AID540317
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	35.4813	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NAD-dependent histone deacetylase SIR2	Saccharomyces cerevisiae S288C	IC50 (µMol)	81.0000	8.8000	8.8000	8.8000	AID204971
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NAD-dependent histone deacetylase SIR2	Saccharomyces cerevisiae S288C	MGC	150.0000	0.4900	0.6700	0.8500	AID204973
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID19538	Half-life period was determined	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Inhibitors of Sir2: evaluation of splitomicin analogues.
AID204971	In vitro inhibition of sirtuin 2 was evaluated using yeast whole cell lysates	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Inhibitors of Sir2: evaluation of splitomicin analogues.
AID204973	Sirtuin 2 inhibitory activity and was reported as minimum growth-stimulating concentration in Saccharomyces cerevisiae	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Inhibitors of Sir2: evaluation of splitomicin analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (61.54)	29.6817
2010's	4 (30.77)	24.3611
2020's	1 (7.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
coumarin 2H-chromen-2-one: coumarin derivative	2.02	1	coumarins	fluorescent dye; human metabolite; plant metabolite
n(g),n(g')-dimethyl-l-arginine N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine	2.06	1	alpha-amino acid
3,4-dihydrocoumarin melilotol: structure in first source. 3,4-dihydrocoumarin : A chromanone that is the 3,4-dihydro derivative of coumarin.	2.02	1	chromanone	plant metabolite
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.02	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.02	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
fenofibrate [no description available]	2.02	1	benzochromenone; delta-lactone; naphtho-alpha-pyrone	platelet aggregation inhibitor; Sir2 inhibitor
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.06	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
bisphenol a 4,4'-isopropylidene diphenol: stimulates proliferative responses and cytokine productions of murine spleen cells and thymus cells in vitro. bisphenol : By usage, the methylenediphenols, HOC6H4CH2C6H4OH, commonly p,p-methylenediphenol, and their substitution products (generally derived from condensation of two equivalent amounts of a phenol with an aldehyde or ketone). The term also includes analogues in the the methylene (or substituted methylene) group has been replaced by a heteroatom.. bisphenol A : A bisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups.	2	1	bisphenol	endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen
1,8-naphthalenedicarboxylic acid anhydride 1,8-naphthalenedicarboxylic acid anhydride: used as seed protector from herbicides	2.02	1	cyclic dicarboxylic anhydride
hydantoins Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.	2.02	1	imidazolidine-2,4-dione
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
glutathione disulfide Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.	2	1	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
2(3h)-benzofuranone 2(3H)-benzofuranone: structure in first source	2.02	1
bw 245c BW 245C: a selective DP receptor agonist. BW 245C : A racemate comprising equimolar amounts of (3R,4S)- and (3S,4R)-BW 245C. A hydantoin-based prostglandin analogue.. 7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid : A imidazolidine-2,4-dione that is 7-(2,5-dioxoimidazolidin-4-yl)heptanoic acid in which the imidazoline ring as substituted at position 3 by a 3-(3-cyclohexyl-3-hydroxypropyl) group.	2.02	1	imidazolidine-2,4-dione; monocarboxylic acid; secondary alcohol
n,n-dimethylarginine N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine. N(omega),N(omega)-dimethyl-L-arginine : A L-arginine derivative having two methyl groups both attached to the primary amino moiety of the guanidino group.	2.06	1	dimethylarginine; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor
sb 203580 [no description available]	2.02	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.02	1	prostaglandins D	human metabolite; mouse metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.05	1	trihydroxyflavone	antineoplastic agent; metabolite
15-deoxyprostaglandin j2 15-deoxyprostaglandin J2: 15d-PGJ2 abbreviation is also used for 15-deoxy-delta(12,14)PGJ2	2.02	1
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.06	1
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	3.53	8

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.46	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.46	2
Blood Clot [description not available]	2.05	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.05	1
Allergic Reaction [description not available]	2.05	1
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	2.05	1
Bacterial Meningitides [description not available]	2.01	1
Group A Strep Infection [description not available]	2.01	1
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	2.01	1
Meningitis, Bacterial Bacterial infections of the leptomeninges and subarachnoid space, frequently involving the cerebral cortex, cranial nerves, cerebral blood vessels, spinal cord, and nerve roots.	2.01	1
Carcinoma, Epidermoid [description not available]	2.01	1
Cancer of Head [description not available]	2.01	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.01	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.01	1

1-keto-1,2,3,4-tetrahydrophenanthrene

Description

Cross-References

Synonyms (34)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (9)

Bioassays (14)

Research

Studies (13)

Market Indicators

Research Demand Index: 12.63

Study Types

1-keto-1,2,3,4-tetrahydrophenanthrene

Description

Cross-References

Synonyms (34)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (9)

Bioassays (14)

Research

Studies (13)

Market Indicators

Research Demand Index: 12.63

Study Types

Related Drugs (21)

Related Conditions (14)